Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady state,...
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The use of denosumab in rare bone diseases in adults: a systematic review from the ECTS Rare Bone Disease Action Group.

The Journal of clinical endocrinology and metabolism·2026
Same author

Transition Care for Young Persons with Rare Bone Mineral Conditions: A Consensus Recommendation from the ECTS Rare Bone Disease Action Group.

Calcified tissue international·2025
Same author

X-Linked Hypophosphatemia Management in Adults: An International Working Group Clinical Practice Guideline.

The Journal of clinical endocrinology and metabolism·2025
Same author

Methodology for the international working group clinical practice guidelines on X-linked hypophosphatemia in children and adults.

Journal of bone and mineral metabolism·2025
Same author

Current Practices in Monitoring Children and Adults With X-linked Hypophosphatemia: A Global Survey of Expert Experience.

The Journal of clinical endocrinology and metabolism·2025
Same author

X-Linked Hypophosphatemia Management in Children: An International Working Group Clinical Practice Guideline.

The Journal of clinical endocrinology and metabolism·2025
Same journal

Increased Prevalence of Coronary Artery Calcification in Patients with Post-Surgical Hypoparathyroidism.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026
Same journal

Alendronate for 6 or 12 months following denosumab discontinuation in women with postmenopausal osteoporosis: A prospective observational study.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026
Same journal

MULTIDIMENSIONAL SPATIAL MAPPING OF EXTRACELLULAR MATRIX: CARTILAGINOUS-OSSEOUS COMPOSITE FORMATION, TENDON INTEGRATION AND VASCULARIZATION DURING SKELETAL GROWTH AND REPAIR.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026
Same journal

Race-Neutral FRAX without BMD outperforms FRAX without BMD in a multiethnic cohort with Diabetes or Hypertension.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026
Same journal

Women's Musculoskeletal Health: Insights from the 2024 National Academies of Sciences, Engineering, and Medicine Report on Chronic Conditions.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026
Same journal

Complement factor H (CFH), an immune factor enhances osteoblast differentiation and correlates with bone density.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026
See all related articles
  1. Home
  2. Is Zoledronic Acid Cost-saving In Daily Practice?
  1. Home
  2. Is Zoledronic Acid Cost-saving In Daily Practice?

Related Experiment Video

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate
13:08

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate

Published on: September 9, 2011

Is Zoledronic acid cost-saving in daily practice?

Willem Lems1, Joop van den Bergh2,3,4, Caroline Wyers2,3,4

  • 1Department of Rheumatology, AmsterdamUMC, Amsterdam, the Netherlands.

Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|June 22, 2026
Summary

No abstract available in PubMed .

More Related Videos

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

Related Experiment Videos

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate
13:08

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate

Published on: September 9, 2011

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021